Abiopharma

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Athira Pharma, Inc. - Common Stock.

NASDAQ symbol attribute type Security_Name was changed. Previous value: Athira Pharma, Inc. - Common Stock. New value: Athira Pharma, Inc. - Common Stock.

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for two Separate Indications

QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics

Controlled-release injectable peptide platform evaluated in preclinical study

Natera - Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth

General Announcement: ISSUANCE OF SHARES PURSUANT TO EXERCISE OF WARRANTS

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth

NASDAQ traded attribute type Test_mode was changed. Previous value: N. New value: Athira Pharma, Inc. - Common Stock.

NASDAQ traded attribute type Security_Name was changed. Previous value: Athira Pharma, Inc. - Common Stock. New value: Athira Pharma, Inc. - Common Stock.

NASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: Athira Pharma, Inc. - Common Stock.

Teva Pharmaceutical Industries Ltd. - Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Appendix 3Y for Lyn Cobley